Servier Group consolidated revenue for the 2022-2023 financial year PAVING THE WAY OF OUR 2030 OBJECTIVES
Servier, an independent international pharmaceutical group, has just published its financial results for the 2022-2023 financial year.
These results was marked by major advances in oncology, confirming the Group’s commitment to developing breakthrough innovations for patients with rare and hard-to-treat cancers.
Key Highlights
- Consolidated sales revenue of €5.327 billion, up 9.2% (+12% at CERi) compared to 2021-2022, driven by strong growth in international sales
- Performance fueled by growth in sales volumes of both brand-name medicines (€4.041 billion, +9.4%) and generics (€1.286 billion, +8.8%)
- Strong performance in oncology sales, which exceeded the symbolic €1 billion mark
- Major breakthroughs in oncology, addressing high unmet medical needs
- A promising and robust R&D pipeline, bringing hope to patients
For more information: servier.com
Follow us on social media: LinkedIn, Facebook, Twitter, Instagram
12/02/2024